NASDAQ OMX

Karolinska Development publishes Interim Report (January - September 2017) and reports a positive result for the third quarter

Dela

STOCKHOLM - October 31, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for January - September 2017. This is the first time since 2014, when Karolinska Development implemented its new strategy, that the company reports a positive quarterly result. The company will host a conference call and an online presentation on October 31, at 2 pm CET - details below. The full report is available on the Company's website.

"It is gratifying that Karolinska Development is starting to see the effects of the strategy shift implemented in 2014. We have posted a positive quarterly result and our portfolio companies are well-positioned to exploit the phase II results that are expected to become available in 2018. The past quarter has seen the value of Karolinska Development's portfolio increase by SEK 229 million, primarily due to the positive results of Umecrine Cognition's phase Ib study and the stock market listing of Xspray Pharma", says Viktor Drvota, CEO, Karolinska Development.

Third Quarter Highlights 2017

  • Karolinska Development posted a positive quarterly result for the first time since the company's strategy shift in 2014.
  • Karolinska Development reports an increase in the value of its holdings in Umecrine Cognition as a result of the company's positive phase Ib-data (October 2017).
  • Umecrine Cognition presented positive phase Ib data for its GR3027 candidate drug, which is being developed for the treatment of hepatic encephalopathy (September 2017).
  • BioArctic announced that it intends to float the company's class B shares on the NASDAQ First North Stockholm exchange (September 2017).
  • Xspray Pharma AB was listed on the NASDAQ First North exchange in Stockholm. When Karolinska Development sold its Xspray holding to new owners in September 2015, an earn-out agreement ensured that it would, in conjunction with a stock market listing, be entitled to receive a holding of 3.74% of the number of shares after the flotation. Based on the share price on 30 September 2017, the value of these shares and the shares owned indirectly via KCIF Co-Investment Fund KB corresponds to SEK 16.2 million, and the value of Karolinska Development's portfolio holdings has, therefore, increased by an equivalent amount (September 2017). 
  • Aprea Therapeutics enrolled the first patient in a phase Ib/II study of the APR-246 candidate drug for patients with platinum-resistant, high-grade serous ovarian cancer (HGSOC) (August 2017).
  • Karolinska Development appointed Fredrik Järrsten to the position of CFO. Fredrik Järrsten will take up his new position in late 2017, succeeding Christian Tange who, after four years at Karolinska Development, is leaving the company to pursue other opportunities. Tange will, however, remain with the company for a period of time after Järrsten takes over as CFO, in order to ensure an orderly handover (August 2017). 

Significant events after the end of Q3 2017

  • Aprea Therapeutics received the last tranche of SEK 188 million in a financing round of totally SEK 437 million from 2016. Aprea also announced the enrollment of the first patient in a phase Ib/II study in esophageal cancer (October 2017).
  • Umecrine Cognition announced that it had secured SEK 20 million in financing for an exploratory, phase IIa study of the company's candidate drug, GR3027, in an additional therapeutic indication area, namely idiopathic hypersomnia (October 2017).
  • BioArctic was listed on the NASDAQ First North exchange. Karolinska Development's holding are valued at SEK 48 million, based on the offering price on 12 October, corresponding to a sum that is 80 times the investment (October 2017).

  • Karolinska Development and KCIF Co-Investment Fund KB announced the divestment of their holdings in Xspray Pharma AB. The transaction generated SEK 13.3 million to Karolinska Development (October 2017).

Financial update

  • Karolinska Development posted a positive quarterly result for the first time since the company's strategy shift in 2014. The net profit totalled SEK 194.1 million (net loss of SEK 17.9 million in Q3 2016), and the earnings per share were SEK 3.0 (SEK -0.3 in Q3 2016).
  • The result of change in portfolio fair value amounted to SEK 212.2 million. The increase was primarily due to the increase in the valuation of the Umecrine Cognition holding due to the positive results from the phase Ib study presented during the quarter, and to the flotation of Xspray Pharma.
  • The total fair value of the portfolio was SEK 674.0 million at the end of September 2017, an increase from SEK 445.0 million at the end of June 2017.
  • Net sales totalled SEK 0.5 million during the third quarter 2017 (SEK 0.4 million in Q3 2016). 
  • Karolinska Development invested a total of SEK 17.1 million in its portfolio companies during the third quarter. Third quarter investments in the portfolio companies by Karolinska Development and other specialised life sciences investors totalled SEK 21.4 million. 
  • Cash and cash equivalents decreased by SEK 23.7 million during the third quarter, totalling SEK 165.4 million on 30 September 2017.
  • The Parent Company's equity at the end of September 2017 was SEK 235.1 million.

Conference Call and Webbcast

The Company will host a conference call on October 31, 2017 at 2 pm CET. Please dial in at one of the following numbers a few minutes before the start of the conference call:

From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22 30
From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following web address:
https://edge.media-server.com/m6/p/95yxnc6z

Host: Viktor Drvota, CEO.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 08:00 am CET on 31 October 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39Pressmeddelande

The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes.  The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c78fdce7-7651-42a8-a621-14088da2cc86 http://www.globenewswire.com/NewsRoom/AttachmentNg/33af2489-a9a8-4bbe-b5f7-78e4c1f29ca2 http://www.globenewswire.com/NewsRoom/AttachmentNg/a16c2

Nasdaq to Deliver Blockchain e-Voting Solution to Strate22.11.2017 10:00Pressmeddelande

South Africa's central securities depository (CSD) will leverage the solution to improve voting efficiencies and increase shareholder participation in South Africa STOCKHOLM, Sweden and JOHANNESBURG, South Africa, Nov.  22, 2017  (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) and Strate (Pty) Ltd, the South African CSD, announced today an agreement for Nasdaq to deliver a new blockchain solution that would bring electronic voting to the South African capital markets. The solution will allow Strate, in conjunction with key stakeholders in the market, to provide general meeting services and give shareholders an easy, user-friendly and secure tool for voting remotely. The solution is based on the successful proof of concept (PoC) developed for Nasdaq's Estonia market. In addition, Strate will contribute to the ongoing market development of e-Voting technology. "We are very excited about our initiative with Nasdaq and what it means for the South African financial markets," said Tan

Immunicum AB: Invitation to Investor Events22.11.2017 08:00Pressmeddelande

Press release November 22, 2017 Invitation to Investor Events Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Aktiespararna Stora Aktiedagen in Gothenburg Date: Monday, November 27, 2017 Presentation Time: 10:10-10:40 CET Location: Svenska Mässan, Mässans Gata 8, Gothenburg Please register to attend at https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg. Immunicum Investor Event in Stockholm Date: Thursday, November 30, 2017 Presentation Time: 18:00-19:00 CET Location: United Spaces, Waterfront Building, Floor 2, Klarabergsviadukt

Immunicum AB: Inbjudan till investerarmöten22.11.2017 08:00Pressmeddelande

Pressmeddelande 22 november 2017 Inbjudan till investerarmöten Immunicum AB (publ), First North Premier: (IMMU.ST), ett bioteknikbolag som utvecklar nya immunaktiverande cancerbehandlingar för ett antal solida tumörer, meddelar dag att VD Carlos de Sousa kommer att presentera bolaget samt bakgrunden till bolagets föreslagna nyemission vid två kommande investerarmöten. Stora Aktiedagen i Göteborg, Aktiespararna Datum: Måndagen den 27 november, 2017 Plats: Svenska Mässan, Mässans gata 8, Göteborg Tid: Kl 10.10 - 10.40 i sal 4 Vänligen anmäl deltagande via https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg. Immunicums investerarmöte i Stockholm Tid: Kl. 18.00 torsdagen 30 november 2017 Plats: United Spaces, Waterfront, Klarabergsviadukten 63 plan 2, Stockholm Det bjuds på lättare förtäring och dryck efter presentationen.

Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme

OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00Pressmeddelande

Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and  Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum